Shattuck Labs Inc. (STTK): Price and Financial Metrics
GET POWR RATINGS... FREE!
STTK POWR Grades
- STTK scores best on the Sentiment dimension, with a Sentiment rank ahead of 90.69% of US stocks.
- The strongest trend for STTK is in Sentiment, which has been heading up over the past 179 days.
- STTK's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).
STTK Stock Summary
- STTK's went public 1.47 years ago, making it older than merely 2.48% of listed US stocks we're tracking.
- The ratio of debt to operating expenses for Shattuck Labs Inc is higher than it is for about merely 0.5% of US stocks.
- In terms of volatility of its share price, STTK is more volatile than 97.76% of stocks we're observing.
- Stocks that are quantitatively similar to STTK, based on their financial statements, market capitalization, and price volatility, are SGTX, AYLA, TMDI, VBLT, and VTGN.
- Visit STTK's SEC page to see the company's official filings. To visit the company's web site, go to www.shattucklabs.com.
STTK Valuation Summary
- In comparison to the median Healthcare stock, STTK's price/sales ratio is 4218.06% higher, now standing at 490.1.
- Over the past 47 weeks, STTK's price/sales ratio has gone up 415.6.
- STTK's price/earnings ratio has moved up 15.7 over the prior 47 weeks.
Below are key valuation metrics over time for STTK.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| STTK | 2021-08-31 | 490.1 | 3.2 | -15.0 | -13.6 |
| STTK | 2021-08-30 | 488.5 | 3.2 | -15.0 | -13.5 |
| STTK | 2021-08-27 | 485.7 | 3.2 | -14.9 | -13.4 |
| STTK | 2021-08-26 | 468.3 | 3.1 | -14.4 | -12.9 |
| STTK | 2021-08-25 | 470.2 | 3.1 | -14.4 | -12.9 |
| STTK | 2021-08-24 | 465.1 | 3.0 | -14.3 | -12.8 |
STTK's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- STTK has a Quality Grade of C, ranking ahead of 29.15% of graded US stocks.
- STTK's asset turnover comes in at 0.006 -- ranking 405th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows STTK's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.006 | 1 | -0.376 |
| 2020-12-31 | 0.050 | 1 | -0.381 |
STTK Price Target
For more insight on analysts targets of STTK, see our STTK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $48.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
STTK Stock Price Chart Interactive Chart >
STTK Price/Volume Stats
| Current price | $3.42 | 52-week high | $31.23 |
| Prev. close | $3.53 | 52-week low | $3.20 |
| Day low | $3.39 | Volume | 176,700 |
| Day high | $3.70 | Avg. volume | 185,362 |
| 50-day MA | $4.11 | Dividend yield | N/A |
| 200-day MA | $11.16 | Market Cap | 144.94M |
Shattuck Labs Inc. (STTK) Company Bio
Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC) platform, a novel class of dual-function fusion proteins with applications in oncology and autoimmune disease. The company’s lead program, SL-279252 (PD1-Fc-OX40L), is being studied in a Phase I trial in collaboration with Takeda Pharmaceuticals. Its technology focuses on immuno-oncology research targeted towards patients with many cancer types, including melanoma, lung, and bladder, by endowing one molecule with multiple functions, with applicability across the entire spectrum of human disease that enables medical researchers to find a quick and painless detection of malignancy for later-stage cancer patients.
Latest STTK News From Around the Web
Below are the latest news stories about Shattuck Labs Inc that investors may wish to consider to help them evaluate STTK as an investment opportunity.
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Shattuck Labs, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 1, 2022 - (NASDAQ: STTK)NEW YORK, Feb. 9, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice on behalf of shareholders of Shattuck Labs, Inc.. Shareholders who purchased shares of STTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment…. |
Shattuck Labs Announces Participation in Upcoming 11th Annual SVB Leerink Global Healthcare ConferenceAUSTIN, TX and DURHAM, NC, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK ), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced that company management will participate in the 11 th Annual SVB Leerink Global Healthcare Conference being held February 14-18, 2022. |
STTK ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 1, 2022 in the Class Action Filed on Behalf of Shattuck Labs, Inc. ShareholdersNEW YORK, Feb. 8, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Shattuck Labs, Inc. (NASDAQ: STTK) alleging that the Company violated federal securities laws. This lawsuit is on behalf of persons or entities who… |
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Shattuck Labs, Inc. (STTK) InvestorsLOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK) securities: (1) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Shattuck’s October 2020 initial publi |
ROSEN, A TOP RANKED LAW FIRM, Encourages Shattuck Labs, Inc. Investors with Losses Over $100K to Secure Counsel Before Important April 1 Deadline in Securities Class Action Commenced by the Firm - STTKNEW YORK, Feb. 7, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Shattuck Labs, Inc. (NASDAQ: STTK): (i) pursuant and/or traceable to the registration statement and related prospectus issued in connection with |
STTK Price Returns
| 1-mo | N/A |
| 3-mo | -35.59% |
| 6-mo | -68.33% |
| 1-year | -87.23% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -59.81% |
| 2021 | -83.76% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...